IGO Q3 2026 slides show strong cash flow despite operational hurdles

IGO reported mixed quarterly results: underlying EBITDA rose to A$119 million and net cash improved to A$327 million, but shares fell 11.24% to A$7.58 as investors focused on Greenbushes underperformance and reduced guidance. Greenbushes spodumene production was flat at 351,000 tonnes, FY production guidance was cut to 1,375-1,425kt from 1,500-1,650kt, and unit cash cost guidance was raised to A$380-420/t. Nova remained a strong offset, with nickel output up 11% to 4,202 tonnes and free cash flow of A$52 million, but Kwinana continued to lag at 51% of nameplate capacity.

Analysis

The market is treating this as a simple “good nickel, bad lithium” quarter, but the deeper read is that IGO is moving from a growth-and-ramp story into a quality-of-operations story. Nova is now behaving like a late-life cash machine: rising output, falling unit costs, and strong free cash flow even as it nears depletion. That matters because every dollar of Nova cash now has higher strategic value — it can either fund remediation at Greenbushes/Kwinana or be returned to holders, making capital allocation the next incremental driver of equity returns.

Greenbushes is the real swing factor, and the risk is not just lower volume; it is a credibility discount that can persist well beyond one quarter. Safety resets plus recovery underperformance create a second-order effect: even if spodumene prices stay firm, the market will haircut the sustainability of EBITDA margins until there is evidence the plant is structurally stabilized. The visible capex reduction is not automatically positive — in a high-incident operating environment, lower spend can read as deferral rather than efficiency, which is a classic setup for another reset later in the year.

The contrarian angle is that consensus may be over-penalizing the stock for near-term lithium operational noise while underestimating the earnings bridge from price recovery. If lithium prices hold anywhere near current levels, Greenbushes can still be a strong cash generator even at lower volumes, so the equity may already be discounting a much worse medium-term outcome than is likely. The cleaner trade, however, is not to chase outright long exposure; it is to separate the cash engine from the execution risk, because Kwinana remains the weakest link and can absorb improved upstream economics through downstream losses.

Catalyst-wise, the next 1-2 quarters matter more than the next 1-2 days: investors need proof that CGP3 offsets legacy plant underperformance and that safety incidents are trending down, not just being managed rhetorically. Failure to show that should keep the stock range-bound to lower, while a couple of clean quarters could force a sharp re-rating given the current depressed sentiment and improving commodity backdrop.

Key Decisions for Investors

• Short the rally in IGO over the next 2-6 weeks if the stock retraces toward pre-print levels without a visible Greenbushes recovery plan execution update; risk is limited if lithium prices stay firm, but upside is capped until operating trust is rebuilt.
• For event-driven investors, buy a 3-6 month call spread on IGO rather than stock: thesis is that Nova cash flow + lithium price recovery supports downside protection, while operational improvement at Greenbushes can re-rate the name; convexity is better than outright equity exposure.
• Pair trade: long a diversified lithium beneficiary with cleaner execution vs short IGO if available in your book; the spread should benefit if the market keeps rewarding operating reliability over asset quality over the next 1-2 quarters.
• If you already own IGO, monetize part of the position into strength and hold a residual stake for a 2-quarter turnaround window; the best risk/reward is capturing Nova-supported cash generation while reducing exposure to Kwinana and safety-driven headline risk.